TAILIEUCHUNG - Hydroxyurea for the Treatment of Sickle Cell Disease

The evidence base described here had significant limitations. Most notably, only two randomized trials addressed hydroxyurea efficacy and safety in patients with sickle cell disease. While the trial enrolling adults was a high-quality trial, it was not long, with only 2 years elapsing since randomization. Two years may be adequate for assessing short-term efficacy, but we had no trial data that made it possible to comment on the long-term efficacy of the drug. We also found no trial data to allow us to assess the effectiveness of this drug in a population who may be asked to take the. | Evidence Report Technology Assessment Number 165 Hydroxyurea for the Treatment of Sickle Cell Disease Prepared for Agency for Healthcare Research and Quality . Department of Health and Human Services 540 Gaither Road Rockville MD 20850 Contract No. 290-02-0018 Prepared by The Johns Hopkins University Evidence-based Practice Center Baltimore MD Investigators Jodi B. Segal . . John J. Strouse . Mary Catherine Beach . . Carlton Haywood . Catherine Witkop . . Haeseong Park . . Renee F. Wilson . Eric B. Bass . . Sophie Lanzkron . AHRQ Publication No. 08-E007 February 2008 This report is based on research conducted by the Johns Hopkins University Evidence-based Practice Center EPC under contract to the Agency for Healthcare Research and Quality AHRQ Rockville MD Contract No. 290-02-0018 . The findings and conclusions in this document are those of the author s who are responsible for its content and do not necessarily represent the views of AHRQ. No statement in this report should be construed as an official position of AHRQ or of the . Department of Health and Human Services. The information in this report is intended to help clinicians employers policymakers and others make informed decisions about the provision of health care services. This report is intended as a reference and not as a substitute for clinical judgment. This report may be used in whole or in part as the basis for the development of clinical practice guidelines and other quality enhancement tools or as a basis for reimbursement and coverage policies. AHRQ or . Department of Health and Human Services endorsement of such derivative products may not be stated or implied. This document is in the public domain and may be used and reprinted without permission except those copyrighted materials noted for which further reproduction is prohibited without the specific permission of copyright holders. Suggested Citation Segal JB Strouse JJ

• Sức khỏe trẻ em
• Oxidation Processes
• Wastewater Treatment
• X Ray Microtomography
• Quality Analysis
• Computer Based
• On Line Assessment
• Journal of Science and Technology
• Treatment effectiveness evaluation of wastewater
• Advanced oxidation processes
• Industrial fried chicken re processing processes
• Re processing wastewater
• Industrial fried chicken
• Journal of Chemistry
• UV vis absorbance values
• Chemical oxygen demand
• Pretreated wastewater characterization
• Environmental advances
• Review of antibiotics treatment
• Advance oxidation processes
• Antibiotics treatment
• Metal ligand charge transfer processes
• Rhodamine B
• Advanced materials and devices
• Photoelectrochemical studies